After a glioblastoma diagnosis, value investor Guy Spier rethought wealth, time and legacy — and the impact he can have on ...

Low-dose aspirin during adjuvant chemotherapy did not significantly reduce risk for recurrence among unselected patients with ...

A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.

Detection is a critical part of bladder cancer evaluation and care, and improved visibility can provide clinicians with ...

Gut microbial and metabolomic alterations are seen years after adenoma resection, according to a study published online May ...

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...

Moderna and Merck present 5-year data for intismeran autogene in combo with Keytruda in patients with high-risk stage III/IV melanoma following complete resection at 2026 ASCO mee ...

Special Report: Optiscan Imaging has reached the halfway mark in its first in-human breast cancer imaging study at The Royal ...

As reported today at the American Society of Clinical Oncology (ASCO) meeting, researchers at the Nagourney Cancer Institute and Metabolomycs, California-based biotechnology companies working with the ...

Moderna, Inc. MRNA stock is trading lower on Monday. The COVID-19 vaccine maker and Merck & Co Inc. MRK reported five-year ...

Wider resection of localized high-risk prostate cancer at surgery may come at the cost of sexual function and urinary incontinence. A phase 2 trial tested the merits of neoadjuvant therapy.